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Aims We evaluated the influence of sacubitril/valsartan on the effects of sodium-glucose cotransporter 2 (SGLT2) inhib-




The EMPEROR-Reduced trial randomized 3730 patients with heart failure and an ejection fraction <_40% to pla-
cebo or empagliflozin (10 mg/day), in addition to recommended treatment for heart failure, for a median of
16 months. A total of 727 patients (19.5%) received sacubitril/valsartan at baseline. Analysis of the effect of neprily-
sin inhibition was 1 of 12 pre-specified subgroups. Patients receiving a neprilysin inhibitor were particularly well-
treated, as evidenced by lower systolic pressures, heart rates, N-terminal prohormone B-type natriuretic peptide,
and greater use of cardiac devices (all P < 0.001) when compared with those not receiving sacubitril/valsartan.
Nevertheless, when compared with placebo, empagliflozin reduced the risk of cardiovascular death or hospitaliza-
tion for heart failure in patients receiving or not receiving sacubitril/valsartan [hazard ratio 0.64 (95% CI 0.45–0.89),
P = 0.009 and hazard ratio 0.77 (95% CI 0.66–0.90), P = 0.0008, respectively, interaction P = 0.31]. Empagliflozin
slowed the rate of decline in estimated glomerular filtration rate by 1.92 ± 0.80 mL/min/1.73 m2/year in patients tak-
ing a neprilysin inhibitor (P = 0.016) and by 1.71 ± 0.35 mL/min/1.73 m2/year in patients not taking a neprilysin inhibi-
tor (P < 0.0001), interaction P = 0.81. Combined inhibition of SGLT2 and neprilysin was well-tolerated.
...................................................................................................................................................................................................
Conclusion The effects on empagliflozin to reduce the risk of heart failure and renal events are not diminished in intensively
treated patients who are receiving sacubitril/valsartan. Combined treatment with both SGLT2 and neprilysin inhibi-
tors can be expected to yield substantial additional benefits.
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Introduction
Pharmacological inhibition of both neprilysin and sodium-glucose
cotransporter 2 (SGLT2) has been shown individually to reduce the
risk of cardiovascular death and hospitalization for heart failure in
patients with heart failure and a reduced ejection fraction. In the
PARADIGM-HF trial, sacubtril/valsartan decreased the risk of cardio-
vascular death and hospitalization for heart failure by 20% as com-
pared with enalapril.1 In the DAPA-HF and EMPEROR-Reduced trials,
SGLT2 inhibition with dapagliflozin or empagliflozin reduced the risk
of cardiovascular death and hospitalization for heart failure by 25% as
compared with placebo.2,3 Modelling analysis has suggested a substan-
tial mitigation of major adverse cardiovascular outcomes when the
two pharmacological approaches are combined.4 However, this ana-
lysis assumed that the effects of neprilysin and SGLT2 inhibition are
additive, i.e. each approach exerts an effect that is neither potentiated
nor attenuated by concurrent treatment with the other.
However, it is not yet clear that the benefits of neprilysin and
SGLT2 inhibition are truly independent of each other. In the large-
scale trial of sacubitril/valsartan, no patients were receiving back-
ground therapy with an SGLT2 inhibitor, and conversely, in the large-
scale trials of SGLT2 inhibitors in patients with type 2 diabetes, no
patients were receiving sacubitril/valsartan. In the DAPA-HF, only
10.7% of the patients with heart failure with a reduced ejection frac-
tion were receiving a neprilysin inhibitor at baseline. As a result, the
number of heart failure events in patients receiving sacubitril/valsar-
tan in this trial was sparse, leading to estimates of a treatment effect
for most outcome measures that were imprecise.5 Accordingly, add-
itional evidence is needed concerning the potential influence of nepri-
lysin inhibition on the effects of SGLT2 inhibitors; this evidence is
important for the formulation of clinical practice guidelines.
As compared with DAPA-HF, the EMPEROR-Reduced trial was
enriched for patients with severe left ventricular systolic dysfunction
(i.e. ejection fraction of 30% or less), and the placebo event rate for the
primary endpoint was 40% higher than in DAPA-HF. More importantly,
the proportion of patients receiving sacubitril/valsartan at baseline in
the EMPEROR-Reduced trial was approximately twice than in DAPA-
HF.3 Therefore, as compared with DAPA-HF, the EMPEROR-Reduced
trial is well-positioned to quantify the influence of neprilysin inhibition
on the effects of SGLT2 inhibitors with a greater degree of precision.
Methods
The EMPEROR-Reduced trial was a randomized, double-blind, parallel-
group, placebo-controlled, and event-driven study, whose design has
been described previously.3 Ethics approval was obtained at each study
site, and all patients provided informed consent to participate in the
study; the registration identifier at ClinicalTrials.gov is NCT03057977.
Participants were men or women with chronic heart failure (New
York Heart Association [NYHA] functional class II, III, or IV) with a left
ventricular ejection fraction <_40%, who were receiving all appropriate
treatments for heart failure, including drugs and cardiac devices, as indi-
cated and as available. We preferentially enrolled patients with a left ven-
tricular ejection fraction of 30% or less by requiring patients with an
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ejection fraction >30% to have been hospitalized for heart failure within
12 months or to have markedly increased levels of N-terminal prohor-
mone B-type natriuretic peptide (NT-proBNP), i.e. >_1000 or >_2500 pg/
mL in those with an ejection fraction of 31–35% or 36–40%, respectively;
these thresholds were doubled in patients with atrial fibrillation.
Patients were randomized double-blind (in a 1:1 ratio) to receive pla-
cebo or empagliflozin 10 mg daily, in addition to their usual therapy for
heart failure. Following entry into the trial, all appropriate treatments for
heart failure or other medical conditions could be initiated or altered at
the clinical discretion of the investigator. Patients were periodically
assessed at study visits for major outcomes, symptoms, and functional
capacity related to heart failure, initiation of new treatments for heart fail-
ure (including neprilysin inhibition), vital signs and biomarkers reflecting
changes in the course of heart failure or the action of SGLT2 inhibitors,
and adverse events. All randomized patients were followed for the oc-
currence of pre-specified outcomes for the entire duration of the trial,
regardless of whether the study participants were taking their study
medications.
The primary endpoint was the composite of adjudicated cardiovascu-
lar death or hospitalization for heart failure analysed as time to first event.
The first secondary endpoint was the occurrence of all adjudicated hospi-
talizations for heart failure (including first and recurrent events). The se-
cond secondary endpoint was the analysis of the slope of the change in
estimated glomerular filtration rate (eGFR) during double-blind treat-
ment, which was supported by an analysis of a composite of serious ad-
verse renal outcomes. The latter was defined as chronic dialysis, renal
transplant, a sustained reduction of >_40% eGFR, or a sustained eGFR
<15 mL/min/1.73m2 (for patients with baseline estimated GFR >_30) or
sustained eGFR <10 mL/min/1.73m2 (for patients with baseline estimated
GFR <30 mL/min/1.73m2). Additional analyses included (i) the individual
components of the primary endpoint; (ii) analyses of the intensity of treat-
ment received during hospitalizations for heart failure, as reported re-
cently6; (iii) changes in the NYHA functional class and the Kansas City
Cardiomyopathy Questionnaire (KCCQ) at 52 weeks; (iv) changes in
haematocrit, uric acid, glycated haemoglobin (HbA1c), NT-proBNP,
body weight, and systolic blood pressure.
Outcome measures and statistical analysis
For time-to-first-event analyses, differences between the placebo and
empagliflozin groups were assessed for statistical significance using a Cox
proportional hazards model, with pre-specified covariates of age, gender,
geographical region, diabetes status at baseline, left ventricular ejection
fraction, and eGFR at baseline. For the analysis of total (first and repeated)
events, between-group differences were assessed using a joint frailty
model, with cardiovascular death (for endpoints including heart failure
events) as a competing risk and using covariates that were used for the
time-to-first-event analyses. To assess differences between the patients
taking and not taking neprilysin inhibitors at baseline, time-to-event and
joint frailty analyses were performed on placebo patients only, using the
same covariate adjustments.
The analysis of the slope in eGFR was based on on-treatment data
using a random coefficient model including age and baseline eGFR as lin-
ear covariates and sex, region, baseline left ventricular ejection fraction,
baseline diabetes status, and baseline eGFR-by-time, treatment-by-base-
line-use-of-neprilysin-inhibition, and treatment-by-time-by-baseline-use-
of-neprilysin-inhibition interactions as fixed effects; the model allows for
randomly varying slope and intercept between patients. To assess differ-
ences between the patients taking and not taking neprilysin inhibitors at
baseline, the same model was used on placebo patients only, but using
baseline eGFR-by-time and baseline use of neprilysin inhibitor-by-time as
the interaction terms.
For vital signs and laboratory measurements, treatment effects were
assessed based on changes from baseline to 52 weeks using a mixed
model for repeated measures that included age and baseline eGFR as lin-
ear covariates and baseline score by visit, visit by treatment, sex, region,
baseline left ventricular ejection fraction, individual last projected visit
based on dates of randomization and trial closure, and baseline diabetes
status as fixed effects. The analysis of changes in NT-proBNP was per-
formed on log-transformed data. For all analyses, the effect of empagliflo-
zin was compared in groups defined by the use or non-use of sacubitril/
valsartan. Effect size estimates (with 95% CIs or standard errors) were
calculated along with between-group and interaction P-values.
Results
Of the 3730 patients who were randomized into the trial, 727
patients (19.5%) were receiving sacubitril/valsartan before the start
of double-blind treatment. The baseline characteristics of the patients
treated or not treated with a neprilysin inhibitor were similar with re-
spect to age, sex, NYHA functional class, aetiology of heart failure,
renal function, history of hospitalizations for heart failure, atrial fibril-
lation and diabetes, and the use of beta-blockers and mineralocortic-
oid receptor antagonists. However, patients treated with a neprilysin
inhibitor were more likely to be recruited in North America; had
lower systolic pressure, heart rate, and lower levels of NT-proBNP;
and were more likely to have received a cardiac device (all P < 0.001).
Specifically, patients who were treated with sacubitril/valsartan were
more likely to have an implantable cardioverter-defibrillation (48.1%
vs. 27.3%) and more likely to have undergone cardiac resynchroniza-
tion therapy (17.6% vs. 10.5%), each P < 0.0001, Table 1. A large pro-
portion of the total number of patients recruited in the USA and
Canada (i.e. 38%) were receiving a neprilysin inhibitor at baseline, as
compared with 20% of those recruited in Europe, and 14% of those
recruited in Latin America and in Asia.
Despite these differences, examining only the patients in the pla-
cebo group, patients treated or not treated with a neprilysin inhibitor
were similar with respect to (i) the combined risk of cardiovascular
death and hospitalization (21.2 vs. 21.0 events per 100 patient-years
of follow-up, P = 0.79); (ii) total number of hospitalizations for heart
failure (121 events in 387 patients vs. 432 events in 1480 patients,
P = 0.67), and the rate of decline in eGFR (-2.2 mL/min/1.73 m2/year
vs. –2.3 mL/min/1.73 m2/year, P = 0.99), in the neprilysin inhibitor and
the no neprilysin inhibitor groups, respectively. During the course of
double-blind treatment, among patients not treated with sacubitril/
valsartan, 131 (8.9%) of the patients in the placebo group and 121
(7.9%) of the patients in the empagliflozin group were initiated on
therapy with a neprilysin inhibitor following randomization.
Effect on hierarchically ranked
endpoints
The influence of background therapy with sacubitril/valsartan on the
effects of empagliflozin on the three major hierarchically ranked end
points is shown in Table 2. When compared with placebo, empagliflo-
zin reduced the combined risk of cardiovascular death or hospitaliza-
tion for heart failure by 23% in the patients not taking a neprilysin
inhibitor and by 36% in the patients taking a neprilysin inhibitor, haz-
ard ratios of 0.77 (95% CI 0.66–0.90), P = 0.0008 and 0.64 (95% CI
0.45–0.89), P = 0.009, respectively. Empagliflozin decreased the total


















..number of hospitalization for heart failure by 29% in the patients
not taking a neprilysin inhibitor and by 35% in the patients taking a
neprilysin inhibitor, hazard ratios of 0.71 (95% CI 0.58–0.88),
P = 0.002 and 0.65 (95% CI 0.42–1.00), P = 0.052, respectively,
Figure 1. When compared with placebo, empagliflozin slowed the
rate of decline in eGFR by 1.71 ± 0.35 mL/min/1.73 m2/year in the
patients not taking a neprilysin inhibitor (P < 0.0001) and by
1.92 ± 0.80 mL/min/1.73 m2/year in the patients taking a neprilysin
inhibitor (P = 0.016). All treatment-by-subgroup interaction P-val-
ues for these analyses were >0.05, Table 2.
Effect on other pre-specified heart failure
and renal outcomes
With respect to the treatments received during hospitalizations for
heart failure, when compared with placebo, empagliflozin reduced
..................................................................... .................................................................
....................................................................................................................................................................................................................
Table 1 Baseline characteristics of patients taking and not taking a neprilysin inhibitor at baseline
Patients not taking a neprilysin
inhibitor (n 5 3003)
Patients taking a neprilysin










Age (year) 66.5 ± 11.2 67.4 ± 10.7 66.2 ± 11.4 66.5 ± 11.4 0.191
Women—n (%) 363 (24.5) 351 (23.0) 93 (24.0) 86 (25.3) 0.632
Race—n (%)
White 1038 (70.1) 1089 (71.5) 266 (68.7) 236 (69.4) 0.046
Black 100 (6.8) 97 (6.4) 34 (8.8) 26 (7.6)
Asian 276 (18.6) 284 (18.6) 59 (15.2) 53 (15.6)
Other or missing 66 (4.5) 53 (3.5) 28 (7.3) 25 (7.4)
Region—n (%)
North America 126 (8.5) 138 (9.1) 87 (22.5) 74 (21.8) <0.0001
Latin America 554 (37.4) 554 (36.4) 91 (23.5) 87 (25.6)
Europe 527 (35.6) 550 (36.1) 150 (38.8) 126 (37.1)
Asia 207 (14.0) 219 (14.4) 38 (9.8) 29 (8.5)
Other 66 (4.5) 62 (4.1) 21 (5.4) 24 (7.1)
NYHA functional classification—n (%)
Class II 1110 (75.0) 1158 (76.0) 291 (75.2) 241 (70.9) 0.380
Class III 362 (24.5) 358 (23.5) 93 (24.0) 97 (28.5)
Class IV 8 (0.5) 7 (0.5) 3 (0.8) 2 (0.6)
Body mass index (kg/m2) 27.7 ± 5.3 27.8 ± 5.4 28.2 ± 5.3 28.6 ± 5.9 0.003
LV ejection fraction (%) 27.3 ± 6.1 28.0 ± 5.9 26.7 ± 6.0 26.7 ± 6.3 0.0002
Systolic blood pressure (mmHg) 122.5 ± 15.4 123.4 ± 16.1 117.0 ± 14.4 118.9 ± 14.4 <0.0001
Heart rate (beats/min) 72.1 ± 11.8 71.3 ± 11.9 69.4 ± 11.5 69.7 ± 10.7 <0.0001
NT-proBNP (IQR), median, pg/mL 1954 (1180, 3544) 1956 (1108, 3612) 1727 (1027, 3251) 1570 (955, 2679) 0.0001
Estimated eGFR (mL/min/1.73 m2) 62.7 ± 21.7 61.5 ± 21.7 60.4 ± 20.7 63.5 ± 21.8 0.839
Cardiovascular history—n (%)
Prior myocardial infarction 611 (41.3) 683 (44.8) 173 (44.7) 156 (45.9) 0.291
Hospitalization for HF within 12 months 446 (30.1) 464 (30.5) 128 (33.1) 113 (33.2) 0.136
Atrial fibrillation or atrial flutter 576 (38.9) 575 (37.8) 162 (41.9) 128 (37.6) 0.379
Diabetes mellitus 735 (49.7) 765 (50.2) 194 (50.1) 162 (47.6) 0.635
Treatment of heart failure
Cardiac glycosides 255 (17.2) 236 (15.5) 56 (14.5) 47 (13.8) 0.149
Mineralocorticoid receptor antagonist 1064 (71.9) 1060 (69.6) 291 (75.2) 246 (72.4) 0.093
Beta-blocker 1403 (94.8) 1448 (95.1) 365 (94.3) 317 (93.2) 0.222
Implantable cardioverter-defibrillatora 401 (27.1) 420 (27.6) 192 (49.6) 158 (46.5) <0.0001
Cardiac resynchronization therapyb 153 (10.3) 161 (10.6) 69 (17.8) 59 (17.4) <0.0001
P-values refer to the difference between patients treated or not treated with a neprilysin inhibitor, combining patients in the two randomized treatment groups. Plus-minus val-
ues are mean ± SD. Patients who self-identified with >_1 race or with no race were classified as other.
eGFR, estimated glomerular filtration rate; HF, heart failure; LV, left ventricular; NT-proBNP, N-terminal prohormone B-type natriuretic peptide; NYHA, New York Heart
Association.
aImplantable cardioverter-defibrillator with or without cardiac resynchronization therapy.
bCardiac resynchronization therapy with or without a defibrillator.




















.the risk of the time to the first hospitalization for heart failure requir-
ing intensive care to a similar degree, hazard ratio of 0.64 (95% CI
0.36–1.17) and 0.66 (95% CI 0.49–0.89), respectively, for the neprily-
sin inhibitor and no neprilysin inhibitor groups, respectively; inter-
action P = 0.95. With respect to the time to the first hospitalization
for heart failure requiring intravenous positive inotropic or vasopres-
sor drug or mechanical support or surgical intervention, the effect of
empagliflozin in patients treated with a neprilysin inhibitor was
greater than those not treated with a neprilysin inhibitor; hazard ratio
of 0.45 (95% CI 0.25–0.80) and 0.84 (95% CI 0.66–1.08), respectively,
for the neprilysin inhibitor and no neprilysin inhibitor groups, respect-
ively; treatment-by-subgroup interaction P = 0.049, Table 2.
For several secondary analyses, the magnitude of the effect of
empagliflozin in patients receiving a neprilysin inhibitor was numeric-
ally larger than in those not receiving a neprilysin inhibitor, although
the interaction P-values were >0.05 (Table 2). When compared with
placebo, empagliflozin reduced the risk of cardiovascular death by 5%
in the patients not taking a neprilysin inhibitor and by 27% in the
....................................................... .................................................
....................................................................................................................................................................................................................
Table 2 Effects of empagliflozin in patients taking and not taking a neprilysin inhibitor at baseline
Patients not taking a neprilysin
inhibitor (n 5 3003)
Patients taking a neprilysin











Cardiovascular death or adjudicated hospitaliza-
tion for heart failure [n (%)]
369 (24.9) 310 (20.9) 93 (24.0) 51 (15.0) 0.31
HR 0.77 (0.66–0.90) HR 0.64 (0.45–0.89)
P = 0.0008 P = 0.0094
Total (first and recurrent adjudicated hospital-
izations for heart failure)
432 318 121 70 0.72
HR 0.71 (0.58–0.88) HR 0.65 (0.42–1.00)
P = 0.002 P = 0.052
Slope of decline in eGFR (mL/min/1.73m2/year)
(± SE)
–2.3 ± 0.3 –0.6 ± 0.2 –2.2 ± 0.5 –0.2 ± 0.6 0.81
þ1.71 ± 0.35, P < 0.0001 þ1.92 ± 0.80, P = 0.016
Composite of serious adverse renal outcomes 49 (3.3) 27 (1.8) 9 (2.3) 3 (0.9) 0.71
HR 0.51 (0.32–0.81) HR 0.39 (0.11–1.45)
P = 0.005 P = 0.16
Time-to-first adjudicated hospitalization for
heart failure
266 (18.0) 206 (13.5) 76 (19.6) 40 (11.8) 0.50
HR 0.71 (0.59–0.85) HR 0.61 (0.42–0.90)
P = 0.0002 P = 0.013
Time-to-first adjudicated hospitalization for
heart failure requiring IV positive inotropic or
vasopressor drugs or mechanical or surgical
intervention
132 (8.9) 118 (7.7) 42 (10.9) 16 (4.7) 0.049
HR 0.84 (0.66–1.08) HR 0.45 (0.25–0.80)
P = 0.18 P = 0.007
Time-to-first adjudicated hospitalization for
heart failure requiring admission to ICU or
CCU
105 (7.1) 72 (4.7) 31 (8.0) 17 (5.0) 0.95
HR 0.66 (0.49–0.89) HR 0.64 (0.36–1.17)
P = 0.006 P = 0.15
Cardiovascular death 167 (11.3) 166 (10.9) 35 (9.0) 21 (6.2) 0.37
HR 0.95 (0.76–1.18) HR 0.73 (0.42–1.25)
P = 0.63 P = 0.25
All-cause mortality 213 (14.4) 217 (14.2) 53 (13.7) 32 (9.4) 0.25
HR 0.96 (0.79–1.16) HR 0.73 (0.47–1.13)
P = 0.68 P = 0.15
Time to all-cause mortality, hospitalization for
heart failure or emergent or urgent care visit
for heart failure
379 (25.6) 318 (20.4) 94 (24.3) 51 (15.0) 0.27
HR 0.77 (0.66–0.89) HR 0.63 (0.44–0.88)
P = 0.0006 P = 0.007
NYHA functional class at 52 weeks
Odds ratio for improvement 1.29 (1.05–1.60), P = 0.02 1.39 (0.90–2.14), P = 0.14 0.77
Odds ratio for worsening 0.88 (0.71–1.09), P = 0.24 0.61 (0.38–0.96), P = 0.03 0.15
KCCQ clinical summary score at 52 weeks þ1.64 (0.28–3.01) þ1.68 (-1.13–4.49) 0.98
P = 0.018 P = 0.24
Treatment effects are shown as HR and 95% confidence intervals in parentheses, except for eGFR slope (shown as adjusted mean ± SE). For NYHA class, a benefit of empagli-
flozin is indicated by odds ratios >1.0 for improvement and <1.0 for worsening.
CCU, cardiac care unit; eGFR, estimated glomerular filtration rate; HR, hazard ratios; ICU, intensive care unit; KCCQ, Kansas City Cardiomyopathy Questionnaire; IV, intraven-
ous; NYHA, New York Heart Association; SE, standard error.
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Figure 1 Effect of empagliflozin on total (first and recurrent) hospitalizations for heart failure, according to use of neprilysin inhibition at baseline.
P-value for the interaction of the effect of empagliflozin and the background use of a neprilysin inhibitor was 0.72. A number of patients at risk at spe-
cific time points in each treatment group are displayed below each graph. CI, confidence intervals; HR, hazard ratio. In accordance with usual practice,
cumulative function plots were truncated when the number of patients being followed in individual subgroups became extremely sparse.
Figure 2 Effect of empagliflozin on composite of serious adverse renal outcomes, according to use of neprilysin inhibition at baseline. P-value for
the interaction of the effect of empagliflozin and the background use of a neprilysin inhibitor was 0.71. A number of patients at risk at specific time
points in each treatment group are displayed below each graph. Between-group difference in estimated glomerular filtration rate represents a slowing
of the decline in renal function in the empagliflozin group. CI, confidence intervals; eGFR, estimated glomerular filtration rate; HR, hazard ratio. In ac-
cordance with usual practice, cumulative incidence plots were truncated when the number of patients being followed in individual subgroups became
extremely sparse.






























































































patients taking a neprilysin inhibitor, hazard ratios of 0.95 (95% CI
0.76–1.18) and 0.73 (95% CI 0.42–1.25), respectively. Empagliflozin
reduced the time to first hospitalization for heart failure by 29% in
the patients not taking a neprilysin inhibitor and by 39% in the
patients taking a neprilysin inhibitor, hazard ratios of 0.71 (95% CI
0.59–0.85) and 0.61 (95% CI 0.42–0.90), respectively. Empagliflozin
reduced the risk of the composite of serious adverse renal outcomes
by 49% in the patients not taking a neprilysin inhibitor and by 61% in
the patients taking a neprilysin inhibitor, hazard ratios of 0.51 (95% CI
0.32–0.81) and 0.39 (95% CI 0.11–1.45), respectively, Figure 2. The
latter analysis was based on only 12 events. For changes in NYHA
functional class at 52 weeks, empagliflozin-treated patients had a
higher odds of showing improvement, odds ratios of 1.39 (95% CI
0.90–2.14) and 1.29 (95% CI 1.05–1.60) for patients taking or not tak-
ing a neprilysin inhibitor, respectively. Similarly, empagliflozin-treated
patients had a lower odds of showing worsening of NYHA functional
class, odds ratios of 0.61 (95% CI 0.38–0.96) and 0.88 (95% CI 0.71–
1.09), for patients taking or not taking a neprilysin inhibitor, respect-
ively. For the KCCQ clinical summary score, the effects of empagliflo-
zin were similar in patients receiving or not receiving a neprilysin
inhibitor, Table 2.
Effect on vital signs, biomarkers, and
safety
Treatment with a neprilysin inhibitor did not influence the effect
of empagliflozin on haemoglobin A1c, uric acid, N-terminal
proBNP, or bodyweight, Table 3. As compared with placebo, sys-
tolic blood pressure declined by a mean of 1–2 mm Hg shortly
during initiation of treatment (at Week 4), and by 1 mm Hg after
52 weeks; the magnitude of these decreases was not influenced by
background therapy with sacubitril/valsartan (interaction P = 0.59
and P = 0.57, respectively). Additionally, the frequency of reports
of adverse events related to hyperkalaemia or hypokalaemia,
hypotension, or hypoglycaemia were similar in placebo- or
empagliflozin-treated patients and was not influenced by back-
ground neprilysin inhibition, Table 4. When analysing treatment-
by-neprilysin inhibitor interactions, the use of empagliflozin in
neprilysin inhibitor-treated patients was associated with a numer-
ically higher frequency of volume depletion but numerically lower
frequency of worsening renal function (as compared with patients
receiving empagliflozin but not treated with a neprilysin inhibitor),
although the between-group difference generally represented
only 10–20 events.
Discussion
Most treatments for chronic heart failure and a reduced ejection frac-
tion have been evaluated in patients who were receiving background
treatment with drugs that had been previously shown to reduce mor-
bidity and mortality. The large-scale trials with beta-blockers were
carried out in patients already receiving inhibitors of the renin-
angiotensin system.7–9 Mineralocorticoids were initially found to be
effective in a trial that enrolled few patients receiving a beta-blocker,10
but were subsequently shown to exert similar benefits in a population
well-treated with inhibitors of the sympathetic nervous system.11
Neprilysin inhibition was shown to reduce morbidity and mortality in
patients who were already receiving inhibitors of the renin-
angiotensin system, beta-blockers, and mineralocorticoid receptor
antagonists.1 However, in the first large-scale trial of SGLT2 inhibition
in heart failure with a reduced ejection fraction (DAPA-HF), only
10.7% of patients were treated with a neprilysin inhibitor.2 Although
the effects of dapagliflozin were numerically similar in patients regard-
less of treatment with sacubitril/valsartan, there were fewer than 100
primary endpoint events in patients receiving both sacubitril/valsartan
and dapagliflozin, leading to estimates that were imprecise. For the
analysis of most secondary variables in that trial, the confidence inter-
vals for the effect of dapagliflozin in patients receiving a neprilysin in-
hibitor were wide, with upper bounds exceeding 1.0.
Although the EMPEROR-Reduced trial was 20% smaller than
DAPA-HF, we studied patients in whom the incidence of cardio-
vascular death and hospitalization for heart failure was 40% higher
than in DAPA-HF,3 and the proportion of patients receiving a
neprilysin inhibitors was approximately twice that in DAPA-HF.
As a result, our analyses of the influence of empagliflozin on heart
failure events were based on 50% more events than observed in
DAPA-HF, thereby affording a greater degree of precision of our
estimates. As in DAPA-HF, we found that background therapy
with a neprilysin inhibitor did not diminish the treatment benefits
of the SGLT2 inhibitor, and in fact, for most endpoints, the magni-
tude of the effect of empagliflozin in patients receiving sacubitril/
valsartan was numerically larger than in those not receiving a
neprilysin inhibitor, although the interaction P-values were gener-
ally not statistically significant. For all of these reasons, for each of
our three major hierarchical endpoints, we were able to demon-
strate a significant or near-significant benefit of empagliflozin (P-
values ranging from 0.052 to 0.009), even when the analysis of the
effect of empagliflozin was confined only to patients receiving
sacubitril/valsartan. This was true both for the effect of empagliflo-
zin to reduce the risk of heart failure events as well as the effect of
the drug to slow the progression of renal disease.
The ability of empagliflozin to produce both cardiac and renal ben-
efits in patients receiving sacubitril/valsartan is particularly note-
worthy since patients receiving the neprilysin inhibitor were
exceptionally well-treated with currently recommended drugs and
devices. As compared with patients not treated with sacubitril/valsar-
tan, systolic blood pressure and circulating levels of NT-proBNP at
baseline were meaningfully lower in patients treated with a neprilysin
inhibitor than those who were not; they also had lower heart rates,
potentially indicative of the use of higher doses of beta-blockers. The
use of cardiac devices was nearly twice as great in patients treated
with sacubitril/valsartan than those who were not; nearly 50% of
patients treated with a neprilysin inhibitor had an implantable
cardioverter-defibrillator. Yet, despite the greater intensity of back-
ground therapy for heart failure, SGLT2 inhibition with empagliflozin
exerted favourable effects on heart failure events and on the progres-
sion of renal disease that were not attenuated (and were often nu-
merically greater) than those seen in patients not receiving a
neprilysin inhibitor. This benefit was achieved with a minimal incre-
mental reduction in systolic blood pressure, either following initiation
of therapy or during long-term treatment, and combination treat-
ment was generally well-tolerated.
The lack of an adverse interaction between SGLT2 inhibitors and
sacubitril/valsartan reinforces the current belief that these two















..classes of drugs have distinctly different mechanisms of action.
Sacubitril/valsartan potentiates the effects of endogenous vasodila-
tory peptides that appear to act primarily through increasing levels of
intracellular cyclic GMP,12 although other mediators may be
involved.13 In contrast, although the mechanism of action of SGLT2
inhibitors has not yet been fully elucidated, these drugs act
intracellularly to reduce oxidative stress and mitigate proinflamma-
tory pathways, possibly through an effect to enhance nutrient depriv-
ation signalling.14,15 Whereas neprilysin inhibitors exert striking
effects to reduce NT-proBNP and may produce symptomatic hypo-
tension during initiation of treatment,16,17 SGLT2 inhibitors have only
modest effects on circulating natriuretic peptides,18 and initiation of
......................................................... ....................................................
....................................................................................................................................................................................................................
Table 3 Changes in vital signs and biomarkers at 52 weeks in patients randomized to placebo and empagliflozin,
according to baseline use of a neprilysin inhibitor
Patients not taking a neprilysin
inhibitor (n 5 3003)
Patients taking a neprilysin











Systolic blood pressure (mm Hg)
At 4 weeks –1.7 ± 0.3 –3.0 ± 0.3 –1.4 ± 0.7 –3.3 ± 0.7 0.59
–1.4 ± 0.5 (P = 0.005) –1.9 ± 1.0 (P = 0.048)
At 52 weeks –1.8 ± 0.5 –2.4 ± 0.4 –0.7 ± 0.9 –2.1 ± 1.0 0.57
–0.6 ± 0.6 (P = 0.38) –1.4 ± 1.3 (P = 0.29)
Bodyweight (kg) þ0.08 ± 0.15 –0.71 ± 0.14 þ0.06 ± 0.29 –0.81 ± 0.31 0.87
–0.80 ± 0.21 (P = 0.0001) –0.87 ± 0.42 (P = 0.04)
Glycated haemoglobin (%) –0.12 ± 0.05 –0.30 ± 0.05 –0.11 ± 0.09 –0.21 ± 0.10 0.65
–0.18 ± 0.07 (P = 0.0074) –0.11 ± 0.14 (P = 0.44)
Uric acid (mg/mL) –0.01 ± 0.05 –0.92 ± 0.05 –0.18 ± 0.09 –1.17 ± 0.10 0.59
–0.91 ± 0.07 (P < 0.0001) –0.99 ± 0.14 (P < 0.0001)





Haematocrit (%) –0.26 ± 0.11 þ2.04 ± 0.11 –0.86 ± 0.22 þ1.69 ± 0.24 0.49
þ2.29 ± 0.16, P < 0.0001 þ2.55 ± 0.33, P < 0.0001
For all variables except for NT-proBNP, changes are shown as adjusted mean ± standard error. Because of the exceptional non-normal distribution, changes in NT-proBNP are
shown as the ratio of geometric means and 95% confidence intervals. Changes in glycated haemoglobin were measured in patients with diabetes, i.e. 735 placebo-treated
patients and 765 empagliflozin-treated patients among those not receiving a neprilysin inhibitor at baseline and in 194 placebo-treated patients and 162 empagliflozin-treated
patients among those receiving a neprilysin inhibitor at baseline.
NT-proBNP, N-terminal prohormone B-type natriuretic peptide.
...................................................................................... ..............................................................................
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Table 4 Frequency of selected adverse events in placebo and empagliflozin-treated patients, according to baseline
use of a neprilysin inhibitor









Serious adverse events 702 (47.6) 631 (41.4) 194 (50.1) 141 (41.5)
Hypotension 124 (8.4) 132 (8.7) 39 (10.1) 44 (12.9)
Symptomatic hypotension 75 (5.1) 76 (5.0) 28 (7.2) 30 (8.8)
Volume depletion 144 (9.8) 146 (9.6) 40 (10.3) 51 (15.0)
Hyperkalaemia 98 (6.6) 89 (5.8) 29 (7.5) 20 (5.9)
Hypokalaemia 24 (1.6) 30 (2.0) 5 (1.3) 5 (1.5)
Worsening renal function 141 (9.6) 143 (9.4) 51 (13.2) 32 (9.4)
Acute kidney injury 38 (2.6) 25 (1.6) 17 (4.4) 10 (2.9)
Confirmed hypoglycaemia 22 (1.5) 22 (1.4) 6 (1.6) 5 (1.5)
Shown are adverse events while on study medication and recorded up to 7 days following discontinuation of the study medications.



























































































treatment is not generally associated with meaningful decreases in
blood pressure. Both neprilysin inhibitors and SGLT2 inhibitors have
favourable effects to slow the decline in renal function in patients
with heart failure and a reduced ejection fraction,3,19 although the
magnitude of the effect of SGLT2 inhibitors is larger than that of
neprilysin inhibitors, and their use is accompanied by a reduced risk
of serious adverse renal outcomes.3,20 Conversely, the effect of
neprilysin inhibitors to reduce the risk of cardiovascular death is
more firmly established than that of SGLT2 inhibitors.1,21
The results of the current study should be considered in light of its
strengths and limitations. The study evaluated the influence of nepri-
lysin inhibition on the effects of empagliflozin across multiple end-
points, which were analysed based on larger number of treated
patients and a greater number of events than the DAPA-HF trial. Yet,
the total database with the combined use of SGLT2 inhibitors and
neprilysin inhibitors in the EMPEROR-Reduced trial is still smaller
than would be seen in a dedicated trial where the use of neprilysin
inhibitors was mandated or highly prevalent. Nevertheless, a recent
meta-analysis that evaluated the influence of sacubitril/valsartan on
the risk of cardiovascular death and hospitalization for heart failure,
based on the combined results of the DAPA-HF and EMPEROR-
Reduced trials, analysed nearly 250 events observed in 1230 patients
who were treated with a neprilysin inhibitor.22 In this meta-analysis,
the results across the two trials were highly concordant, with no evi-
dence of heterogeneity. Combining the results takes advantage of
the fact that the two trials studied complementary but overlapping
groups of patients, which cover the full spectrum of patients with
heart failure and a reduced ejection fraction.21,22 Nevertheless, these
analyses do not provide any insights concerning the effects of neprily-
sin inhibitors in patients who were receiving background therapy
with SGLT2 inhibitors. Examination of this question in a large-scale is
not feasible, and given the lack of interaction seen in the meta-
analysis, is unlikely to yield results that differ from that of the effects
of neprilysin inhibition in the absence of SGLT2 inhibition.
In conclusion, the effects on empagliflozin to favourably affect the
clinical course of heart failure and kidney function are not influenced
by concurrent therapy with sacubtril/valsartan. Concurrent treat-
ment with both neprilysin and SGLT2 inhibitors is well-tolerated and
is expected to yield substantial incremental benefits.4 Efforts should
be directed towards developing and implementing strategies that
would encourage combined use of both classes of drugs in a broad
range of patients with heart failure and a reduced ejection fraction.
Data availability
Data will be made available upon request in adherence with transpar-
ency conventions in medical research and through requests to the cor-
responding author. The executive committee of EMPEROR has
developed a comprehensive analysis plan and numerous pre-specified
analyses, which will be presented in future scientific meetings and pub-
lications. At a later time point, the full database will be made available
in adherence with the transparency policy of the sponsor (available at
https://trials.boehringer-ingelheim.com/transparency_policy.html).
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Corrigendum to:/Retraction: Clinical presentation, management and 6-month outcomes in women with peripartum cardiomyopathy, an
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In the originally published version of this manuscript, Appendix 1 – PPCM was omitted from the supplementary data. This has now been
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